PSG announces the results of its extensive research on the latest trends in specialty drug benefits. This exclusive research offers comprehensive insights to assist employers,…
Amid evolving Medicare regulations and market dynamics, payer leaders face unprecedented challenges in maintaining profitability while delivering quality care. Join our team of Medicare experts…
Transforming pharmacy benefit strategy into execution for Modular PBA models In today’s prescription drug landscape, where costs continue to soar and patients struggle to access…
A Snippet From The 2025 Payer’s Guide to GLP-1 Drugs In recent years, GLP-1 drugs have become increasingly popular for their effectiveness in managing obesity.
In an increasingly demanding and ever-changing healthcare environment, project management missteps can derail even the most promising initiatives. Join our industry experts as they reveal…
When a health plan changed PBMs for the first time in 10 years, PSG helped ensure a seamless implementation and transition. 1M testing claims validated…
Advancing Industry Understanding with Research For over three decades, PSG has been the expert voice in all aspects of managing pharmacy benefits. Our comprehensive research…
Leveraging Stelara Biosimilars Could be a Valuable Savings Strategy in 2025 Since its introduction in 2009, Stelara (sold by Janssen) has emerged as a critical…
DALLAS, TX – December 12, 2024 – Pharmaceutical Strategies Group (“PSG”), an EPIC company, announces the appointment of Travis Baughn as Vice President of…
The US Food and Drug Administration (FDA) approved the latest multimillion gene therapy. On November 13, 2024, the FDA approved Kebilidi (eladocagene exuparvovec-tneq), a gene…
